share_log

Needham Reiterates Buy on Avadel Pharmaceuticals, Maintains $22 Price Target

Benzinga ·  Oct 18 17:53

Needham analyst Ami Fadia reiterates Avadel Pharmaceuticals (NASDAQ:AVDL) with a Buy and maintains $22 price target.

Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more
    Write a comment